27
May 2026
Degrading mutant KRAS protein induces greater lung cancer regression
KRAS is one of the oncogenes most frequently altered in cancer, mutated in approximately one-third of lung adenocarcinomas.
-
Life can be betterWe are developing drug products isolated from plant extracts
with history in traditional medicine. -
Improving healthImproving health and wellbeing of the people
is our ultimate goal at Mercury Pharmaceuticals. -
ENTREPRENEURIAL MINDSETHands-on approach to manage projects with proactivity and flexibility.
Welcome to Mercury Pharmaceuticals
We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
OUR Science
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
- NeuroscienceAmong the global leaders in Neuroscience
- OncologyTreatments for niche cancers.
- Research & Development Building a sustainable R&D pipeline.
- Clinical trialsTesting new treatments and ensure their efficacy and safety by conducting clinical trials.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
27
May 2026
Prenatal therapy for cystic fibrosis improves lifelong health outcomes
This Cystic Fibrosis Awareness Month, Children's Hospital Colorado (Children's Colorado) is highlighting a growing shift in care: starting cystic fibrosis treatment before birth to improve lifelong health outcomes and reduce hospital stays.
27
May 2026
Mount Sinai opens integrated clinical center for womens health
The Mount Sinai Health System is opening the Carolyn Rowan Center for Women's Health and Wellness, a transformative new model for women's health that brings together multidisciplinary clinical expertise, structured care pathways, and leading-edge research innovation to deliver more personalized, comprehensive care for women across the entire lifespan.
27
May 2026
Study reveals how immune cells alter vascular plaque formation
A new LMU study shows how differently immune cells influence the formation of dangerous vascular deposits - and identifies miR-147 as a potential starting point for future therapies.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.